Syros Pharmaceuticals Shares Plummet Premarket After Study …
2 days ago — Syros shares, which closed Tuesday at $2.73, were recently down 85% at about 42 cents in premarket trading. Write to Colin Kellaher at [email protected] About Dow Jones Newswires
Syros stock craters after lead cancer therapy flops in Phase III trial
2 days ago — Syros’s stock was showing an upward trend after the value drastically declined in August after the news of a potential Phase II SELECT-AML-1 trial failure broke.
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
--SELECT-MDS-1 Did Not Meet its Primary Endpoint ---- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps --CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial ...
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
2 days ago — CAMBRIDGE, Mass., November 12, 2024--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of ...
Syros Pharmaceuticals says SELECT-MDS-1 trial did not meet …
3 days ago — TipRanks. Nov. 12, 2024, 03:41 PM. Syros Pharmaceuticals (SYRS) announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk ...
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
3 days ago — Syros Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 [email protected] Investor Amanda Isacoff Precision AQ 212-362-1200 [email protected] Contacts
Syros Pharmaceuticals, Inc. (SYRS) Latest Stock News
Get the latest Syros Pharmaceuticals, Inc. (SYRS) stock news and headlines to help you in your trading and investing decisions.
Syros Pharmaceuticals, Inc. (SYRS)
Latest News Nov 12, 2024. Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression. View All News
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
2 days ago — Syros’ stock price fell precipitously after the news was announced. Topline data from the Phase III study showed that tamibarotene combined with azacitidine hit a complete response (CR) rate of 23.8% in newly diagnosed patients with higher-risk myelodysplastic syndrome (HR-MDS) with an overexpression of the RARA gene.
Syros flunks phase 3 blood cancer trial, triggering loan default and ...
2 days ago — Syros said the repayment of $43.6 million may be accelerated as a result of the default. The biotech ended September with $58.3 million. Related. Syros’ stock up after sharing early, mid-stage ...
- Some results have been removed